Galaxy Biomedical Investment Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 322 million compared to CNY 178.32 million a year ago. Revenue was CNY 322 million compared to CNY 178.32 million a year ago. Net loss was CNY 14.68 million compared to CNY 1.76 million a year ago. Basic loss per share from continuing operations was CNY 0.0133 compared to CNY 0.0016 a year ago. Diluted loss per share from continuing operations was CNY 0.0133 compared to CNY 0.0016 a year ago.